Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-modality Therapy for High Risk and Low Volume Metastatic Prostate Cancer
NCT03436654Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2018
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of apalutamide, Abiraterone Acetate Tablets (I) in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Started Jun 2018; status: active, not recruiting.
02
Drugs
apalutamideAbiraterone Acetate Tablets (I)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03436654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03436654.